Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
You have accessRestricted Access

Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms' tumor.

S G Carlson, E Eng, E G Kim, E J Perlman, T D Copeland and B J Ballermann
JASN October 1998, 9 (10) 1873-1880; DOI: https://doi.org/10.1681/ASN.V9101873
S G Carlson
Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E Eng
Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E G Kim
Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E J Perlman
Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T D Copeland
Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B J Ballermann
Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading

Abstract

The human gene set was originally identified as a component of the set-can fusion gene produced by a somatic translocation event in a case of acute undifferentiated leukemia. In the developing kidney, set was highly expressed in the zone of nephron morphogenesis. Recently, SET was shown to be a potent and specific inhibitor of protein phosphatase 2A, a family of major serine/threonine phosphatases involved in regulating cell proliferation and differentiation. The current study sought to define further the role of SET in the regulation of renal cell proliferation and tumorigenesis. The mRNA encoding SET was expressed at much higher levels in transformed human and rodent cell lines than in cultured renal epithelial and primary endothelial cells. Consistent with a role for SET in cell proliferation, set mRNA expression was markedly reduced in cells rendered quiescent by serum starvation, contact inhibition, or differentiation. Previous findings during renal development were extended by demonstrating that SET protein expression is also much greater in developing rat and human kidney than in fully differentiated, mature kidney. Finally, high levels of set mRNA and SET protein expression were found in Wilms' tumor, but not in renal cell carcinoma, adult polycystic kidney disease or in transitional cell carcinoma.

  • Copyright © 1998 by American Society of Nephrology
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology
Vol. 9, Issue 10
1 Oct 1998
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
View Selected Citations (0)
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms' tumor.
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms' tumor.
S G Carlson, E Eng, E G Kim, E J Perlman, T D Copeland, B J Ballermann
JASN Oct 1998, 9 (10) 1873-1880; DOI: 10.1681/ASN.V9101873

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms' tumor.
S G Carlson, E Eng, E G Kim, E J Perlman, T D Copeland, B J Ballermann
JASN Oct 1998, 9 (10) 1873-1880; DOI: 10.1681/ASN.V9101873
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Info & Metrics
  • View PDF

Cited By...

  • Antagonizing SET Augments the Effects of Radiation Therapy in Hepatocellular Carcinoma through Reactivation of PP2A-Mediated Akt Downregulation
  • PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis
  • JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia
  • Pseudopodial Actin Dynamics Control Epithelial-Mesenchymal Transition in Metastatic Cancer Cells
  • The PP2A inhibitor SET regulates natural killer cell IFN-{gamma} production
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire